Research and Markets: Genzyme Corporation: Pharmavitae Profile

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/11e326/genzyme_corporatio) has announced the addition of the "Genzyme Corporation: PharmaVitae Profile" company profile to their offering.

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Key reasons to purchase this title

  • Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector
  • See how the company's core products of Cerezyme, Fabrazyme and Myozyme/Lumizyme will continue to act as the primary sales growth drivers
  • Assess the impact of the recent contamination of the Allston manufacturing facility on the company's performance through 2009

Key Topics Covered:

Chapter 1 About this profile

Chapter structure

Chapter 2 Executive summary

Chapter 3 Quarterly news update

Chapter 4 Company introduction

Chapter 5 Company sales

Chapter 6 Company financials

Chapter 7 Key products and competitors

Chapter 8 Appendix

Companies Mentioned:

  • Amgen Inc.
  • AstraZeneca PLC
  • Chugai Pharmaceutical Co. Ltd
  • Genentech, Inc.
  • Genzyme Corporation
  • Gilead Sciences, Inc.
  • IMS Health
  • Wyeth

For more information visit http://www.researchandmarkets.com/research/11e326/genzyme_corporatio

Source: Datamonitor



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.